Overview / Abstract: |
As biosimilar guidance evolves in the United States and these biologics are studied and FDA-approved for use, it will be important for clinicians to understand how biosimilars’ characteristics overlap with, and differ from, other available biologic therapies, so that effective treatment selection and monitoring, and related patient education, can be achieved. |
Expiration |
Sep 29, 2017 |
Credits / Hours |
30 Minutes |
Accreditation |
ACCME, ACPE |
Presenters / Authors / Faculty |
Jonathan Kay, MD Edward Li, PharmD, MPH, BCOP Andrew D. Zelenetz, MD, PhD |
Activity Specialities / Related Topics |
Dermatology, Family Medicine, Gastroenterology / GI, Nephrology, Oncology / Cancer / Radiation Therapy, Primary Care, Rheumatology / Arthritis |
Sponsors / Supporters / Grant Providers |
Pfizer |
Keywords / Search Terms |
The France Foundation Biosimilars Free CE CME |